Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Infinium Pharma
Quarter-by-quarter operating performance
Financials of Infinium Pharma
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 39 | 71 | 99 | 114 | 136 | 156 | 190 |
| Expenses + | 36 | 66 | 89 | 98 | 117 | 136 | 168 |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 11% |
| Other Income + | 1 | 1 | 1 | 1 | 2 | -1 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | 20% |
| Net Profit + | 1 | 3 | 7 | 10 | 12 | 8 | 14 |
| EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 | 5.23 | 7.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Infinium Pharma
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| Borrowings + | 9 | 11 | 23 | 29 | 11 | 52 | 0 |
| Other Liabilities + | 9 | 17 | 23 | 19 | 15 | 37 | 54 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Fixed Assets + | 4 | 5 | 4 | 19 | 20 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Other Assets + | 18 | 26 | 46 | 52 | 66 | 144 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
Financials of Infinium Pharma
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3 | 7 | 12 | 9 | -13 | -29 | |
| Cash from Investing Activity + | -1 | -5 | -7 | -5 | -4 | -27 | |
| Cash from Financing Activity + | -1 | -1 | -2 | -3 | 23 | 79 | |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | |
| CFO/OP | 137% | 168% | 137% | 73% | -51% | -131% |
Financials of Infinium Pharma
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | 32% | 38% | 36% | 28% | 15% | 13% |
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p